Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRumble, J Ren
dc.contributor.authorGilbert, Richard Een
dc.contributor.authorCox, Allison Jen
dc.contributor.authorWu, Len
dc.contributor.authorCooper, Mark Een
dc.identifier.citationJournal of Hypertension; 16(11): 1603-9en
dc.description.abstractThe purpose of this study was to assess the role of transforming growth factor (TGF)-beta1 in the development of diabetes-associated mesenteric vascular hypertrophy and in the antitrophic effect of angiotensin converting enzyme inhibitors.Streptozotocin-induced diabetic and control Sprague-Dawley rats were randomly allocated to treatment with the angiotensin converting enzyme inhibitor ramipril or to no treatment and were killed 1 or 3 weeks after the streptozotocin injection. Blood was collected and mesenteric vessels removed. Mesenteric vascular weight was measured and TGF-beta1 and alpha1 (type IV) collagen messenger (m)RNA levels were analysed by Northern analysis. Immunohistochemical analyses for TGF-beta1 and type IV collagen were also performed.The diabetic rats had increased mesenteric vessel weight at 3 weeks but not at 1 week and a concomitant rise in mesenteric TGF-beta1 and in alpha1 (type IV) collagen mRNA levels. Ramipril treatment attenuated mesenteric vessel hypertrophy and prevented the increase in TGF-beta1 and alpha1 (type IV) collagen mRNA levels after 3 weeks of diabetes. The immunohistochemical analysis revealed that diabetes was associated with increased TGF-beta1 and type IV collagen protein and extracellular matrix accumulation in mesenteric vessels, and this increase was reduced by ramipril treatment.These results support the concept that TGF-beta is involved in the changes associated with diabetic vascular disease, and suggest a mechanism by which angiotensin converting enzyme inhibitors exert their antitrophic effects.en
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.pharmacologyen
dc.subject.otherBlood Glucose.drug effectsen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherBlotting, Northernen
dc.subject.otherBody Weight.drug effectsen
dc.subject.otherDiabetes Mellitus, Experimental.complicationsen
dc.subject.otherDiabetic Angiopathies.complications.genetics.metabolismen
dc.subject.otherGene Expression.drug effectsen
dc.subject.otherRNA, Messenger.analysis.geneticsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherTransforming Growth Factor beta.geneticsen
dc.subject.otherVascular Diseases.complications.genetics.metabolismen
dc.titleAngiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Hypertensionen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg, Australiaen
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on May 26, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.